156 filings
ARS
2023 FY
DNLI
Denali Therapeutics Inc
18 Apr 24
Annual report to shareholders
4:05pm
DEFA14A
DNLI
Denali Therapeutics Inc
18 Apr 24
Additional proxy soliciting materials
4:04pm
DEF 14A
DNLI
Denali Therapeutics Inc
Definitive proxy
18 Apr 24
4:03pm
S-3ASR
DNLI
Denali Therapeutics Inc
22 Mar 24
Automatic shelf registration
4:01pm
D
DNLI
Denali Therapeutics Inc
1 Mar 24
$499.73 mm in equity / options, sold $499.73 mm, 11 investors
4:51pm
S-8
9c32tezfhxrglz38
27 Feb 24
Registration of securities for employees
8:21pm
8-K
xml 2ogcvz
27 Feb 24
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:07am
8-K
e60iclm9
27 Feb 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
8:03am
8-K
mhxz9 2hee
16 Feb 24
Regulation FD Disclosure
8:02am
8-K
y8w2mr d8mkgza7l0
8 Jan 24
Regulation FD Disclosure
8:06am
8-K
i0epv
7 Nov 23
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
jsszyr
21 Aug 23
Entry into a Material Definitive Agreement
4:06pm
8-K
n7amen6agbdpy
8 Aug 23
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
egwy4 mh8hvci46i
20 Jun 23
Other Events
7:03am
8-K
z92cro2
5 Jun 23
Other Events
8:12am
8-K
zpkndn1iyo3uv5
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm